CHMP recommends nine drugs in April – first RSV vaccine nears finish line
Eli Lilly, GSK, and BMS, among others, were the recipients of good news after the EMA committee’s meeting this month.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
GSK has taken a large step toward getting the first vaccine against respiratory syncytial virus (RSV), targeting adults in their over-sixties, on the market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends nine drugs in March
For subscribers
